Comparative Effectiveness of Long Term Fingolimod Versus Glatiramer Acetate on Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients With Multiple Sclerosis

Trial Profile

Comparative Effectiveness of Long Term Fingolimod Versus Glatiramer Acetate on Brain Atrophy Rates, Cognition and Patient Reported Outcomes in Patients With Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Fingolimod (Primary) ; Glatiramer acetate
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Most Recent Events

    • 25 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 17 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.
    • 28 Apr 2017 Results (n=120) of preliminary analysis presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top